Spanish biotech firm Oxolife has reported encouraging findings from its Phase II trial of OXO-001, a novel non-hormonal fertility pill designed to aid in vitro fertilization (IVF) outcomes. According to the results presented at the European Society of Human Reproduction and Embryology (ESHRE) 40th Annual Meeting in Amsterdam, OXO-001 demonstrated a notable improvement in pregnancy and live birth rates among participants.
The placebo-controlled trial, known as OXOART2 (NCT05076032), focused on 96 women up to 40 years old who underwent IVF with single embryo transfer using donor eggs. Results indicated that OXO-001 increased pregnancy rates by 10.6% and live birth rates by 6.9% compared to the placebo group.
OXO-001 functions by enhancing the receptivity of the uterine endometrium to embryo implantation. Patients were instructed to take the pill twice daily, starting from one menstrual cycle before embryo transfer and continuing for five weeks thereafter.
The findings underscore the potential of OXO-001 to address the growing demand for effective fertility treatments among women. GlobalData forecasts the female infertility market to reach $2.3 billion by 2033 across key markets including the US, France, Germany, Italy, Spain, UK, and Japan.
The results from this Phase II trial position Oxolife’s OXO-001 as a promising candidate in the realm of fertility therapeutics, offering hope for improved outcomes in IVF procedures.
Related Links:
